Abstract：
OBJECTIVE: To conduct a scoping review of the existing literature and recent developments on prostatic stents for the treatment of benign prostatic hyperplasia (BPH).
METHODS: A comprehensive search was performed on Embase, MEDLINE, and Web of Science to identify English literature on prostatic stents for the treatment of BPH. Additional studies and upcoming devices were identified through grey literature search and expert consultation. Study characteristics and stent information were extracted and tabulated narratively.
RESULTS: Of the 1171 search results, 64 studies were included in this review. iTiND was the prostatic stent with the most long-term evidence. iTiND is a safe and effective minimally invasive treatment for BPH that preserves sexual function. Adverse events are mild and transitory. Emerging stents (e.g. Zenflow, Butterfly, Urocross, and Exime) had 7/64 eligible studies, where no studies had long-term follow-up. These newer stents show promising results for quality of life and BPH symptom management; however, long-term monitoring and head-to-head comparisons are needed.
CONCLUSIONS: Over the last 50 years, prostatic stents have evolved and demonstrated improved clinical efficacy. iTiND provides a safe and effective outpatient treatment of LUTS secondary to BPH preserving erectile and ejaculatory function. Emerging prostatic stents are a promising, effective, and safe intervention in well-selected patients interested in its benefits.
METHODS: A comprehensive search was performed on Embase, MEDLINE, and Web of Science to identify English literature on prostatic stents for the treatment of BPH. Additional studies and upcoming devices were identified through grey literature search and expert consultation. Study characteristics and stent information were extracted and tabulated narratively.
RESULTS: Of the 1171 search results, 64 studies were included in this review. iTiND was the prostatic stent with the most long-term evidence. iTiND is a safe and effective minimally invasive treatment for BPH that preserves sexual function. Adverse events are mild and transitory. Emerging stents (e.g. Zenflow, Butterfly, Urocross, and Exime) had 7/64 eligible studies, where no studies had long-term follow-up. These newer stents show promising results for quality of life and BPH symptom management; however, long-term monitoring and head-to-head comparisons are needed.
CONCLUSIONS: Over the last 50 years, prostatic stents have evolved and demonstrated improved clinical efficacy. iTiND provides a safe and effective outpatient treatment of LUTS secondary to BPH preserving erectile and ejaculatory function. Emerging prostatic stents are a promising, effective, and safe intervention in well-selected patients interested in its benefits.
摘要：
目的：对前列腺支架治疗良性前列腺增生（BPH）的现有文献和最新进展进行范围综述。
方法：在Embase上进行了全面搜索，MEDLINE,和WebofScience确定有关前列腺支架治疗BPH的英文文献。通过灰色文献检索和专家咨询确定了其他研究和即将到来的设备。对研究特征和支架信息进行了提取和列表叙述。
结果：在1171个搜索结果中，该综述包括64项研究。iTiND是最长期证据的前列腺支架。iTiND是一种安全有效的BPH微创治疗方法，可保留性功能。不良事件是轻微和短暂的。新兴支架（例如Zenflow，蝴蝶,Urocross,和Exime)有7/64项合格研究，没有研究进行长期随访。这些较新的支架在生活质量和BPH症状管理方面显示出有希望的结果；然而，需要进行长期监测和头对头比较。
结论：在过去的50年里，前列腺支架的发展和临床疗效的改善。iTiND为BPH继发的LUTS提供安全有效的门诊治疗，以保持勃起和射精功能。新兴的前列腺支架是有前途的，有效,以及对精心挑选的对其益处感兴趣的患者进行安全干预。
方法：在Embase上进行了全面搜索，MEDLINE,和WebofScience确定有关前列腺支架治疗BPH的英文文献。通过灰色文献检索和专家咨询确定了其他研究和即将到来的设备。对研究特征和支架信息进行了提取和列表叙述。
结果：在1171个搜索结果中，该综述包括64项研究。iTiND是最长期证据的前列腺支架。iTiND是一种安全有效的BPH微创治疗方法，可保留性功能。不良事件是轻微和短暂的。新兴支架（例如Zenflow，蝴蝶,Urocross,和Exime)有7/64项合格研究，没有研究进行长期随访。这些较新的支架在生活质量和BPH症状管理方面显示出有希望的结果；然而，需要进行长期监测和头对头比较。
结论：在过去的50年里，前列腺支架的发展和临床疗效的改善。iTiND为BPH继发的LUTS提供安全有效的门诊治疗，以保持勃起和射精功能。新兴的前列腺支架是有前途的，有效,以及对精心挑选的对其益处感兴趣的患者进行安全干预。
